5 terminated, 4 withdrawn, 3 active not recruiting, 3 recruiting. 15 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 5, Withdrawn 4, Active not recruiting 3, Recruiting 3 |
| Phase 1 | 9 | Withdrawn 4, Terminated 3, Active not recruiting 1, Recruiting 1 |
Follow Recurrent B Acute Lymphoblastic Leukemia: new trials by email Literature Review of Recurrent B Acute Lymphoblastic Leukemia trials Research Report on Recurrent B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-11-12 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2019-05-08 | 2026-11-12 |
| Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 53 | 2019-04-03 | 2026-05-13 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Biospecimen Collection, Computed Tomography, Lumbar Puncture - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 40 | 2018-08-13 | 2026-10-06 |
| Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2018-04-18 | 2022-11-04 |
| Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2018-02-15 | 2026-08-10 |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 2 | Active not recruiting | Children's Oncology Group | 80 | 2017-06-19 | 2026-10-01 |
| Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2015-07-15 | 2025-06-08 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
Burkitt Lymphoma (15) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (2) · Disease Progression (1) · Down Syndrome (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1)
DNA Virus Infections (15) · Epstein-Barr Virus Infections (15) · Hemic and Lymphatic Diseases (15) · Herpesviridae Infections (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Infections (15) · Lymphatic Diseases (15) · Lymphoma (15) · Lymphoproliferative Disorders (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Tumor Virus Infections (15) · Virus Diseases (15) · Lymphoma, B-Cell (14)
Vincristine (9) · Cytarabine (8) · Methotrexate (8) · Cyclophosphamide (7) · merphos (7) · Dexamethasone (6) · Biopsy (5) · Calcium Dobesilate (5) · Inotuzumab Ozogamicin (5) · Mercaptopurine (5) · Rituximab (5) · Spinal Puncture (5) · auricularum (5) · dexamethasone 21-phosphate (5) · dexamethasone acetate (5)
M.D. Anderson Cancer Center (8) · Children's Oncology Group (2) · National Cancer Institute (NCI) (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (14) · Puerto Rico (4) · Australia (1) · Canada (1)
Elias Jabbour (3) · Nitin Jain (2) · Elias Jabbour, MD (1) · Eunice S Wang (1) · Jin S Im (1) · Jordan Gauthier (1) · Matthew A Kutny (1) · Matthew J Wieduwilt (1) · Maureen M O'Brien (1) · Neil D Palmisiano (1) · Nicholas Short, MD (1) · Stacy L Cooper (1)
PMID 35622074, PMID 41671463, PMID 38551807, PMID 28859185, PMID 29352703, PMID 35007127, PMID 37131217, PMID 37187201, PMID 37879077, PMID 38207208, PMID 38324336, PMID 39415930, PMID 41026957
U10CA180886 (3), P30CA016672 (2), U10CA180820 (1), U10CA180821 (1)